Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Aumolertinib Combined With Anlotinib in Advanced EGFR-Mutant NSCLC With TP53 Co-Mutation
NCT05778149Phase 2Not yet recruiting
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
- Start
- Mar 2023
- Primary completion
- Mar 2025
- Modality
- Small Molecules
01
Overview
A Phase 2 trial of almonertinib, anlotinib in non-small cell lung cancer (NSCLC), sponsored by Tianjin Medical University Cancer Institute and Hospital. Planned start Mar 2023; status: not yet recruiting.
02
Drugs
almonertinibanlotinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT05778149.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05778149.